Orthocell Chairman John Van Der Wielen recently spoke with podcast host Chris Judd on Talk Ya Book to discuss the Company’s journey and exciting plans for global expansion with its regenerative medicine technologies.

From his experience during the GFC at Lloyd’s Banking Group to leading Orthocell’s strategic expansion, John shares valuable insights on building a sustainable healthcare company. He discusses Orthocell’s innovative nerve repair technology, its strong manufacturing capabilities, and the significant market opportunity ahead, particularly in the US.

“The majority of biotechs do not manufacture their own product. They invent the product, they do the research, but we’ve built the manufacturing labs in Western Australia. We’ve got capacity to produce about 100,000 units, and a nice problem to have is that we have to add another module to produce more product. But the benefit for it as an investor is we own that manufacturing margin… and that’s incredibly powerful.”

Have a listen: